Ipsen

Albireo Pharma, Inc. is a biopharmaceutical company based in Boston, Massachusetts, specializing in the development and commercialization of innovative bile acid modulators aimed at treating rare pediatric liver diseases and gastrointestinal disorders. The company's lead product candidate, odevixibat, is an ileal bile acid transporter inhibitor currently undergoing phase III clinical trials for the treatment of progressive familial intrahepatic cholestasis, biliary atresia, alagille syndrome, and other cholestatic liver diseases. Additionally, Albireo is advancing Elobixibat, which targets chronic constipation and other functional gastrointestinal disorders, as well as nonalcoholic steatohepatitis. The company is also developing A3384 for gastrointestinal diseases and has established a licensing agreement with EA Pharma for the development and commercialization of elobixibat.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery, development, and commercialization of novel epigenetic medicines for cancer and other serious diseases. The company has developed Tazemetostat, an EZH2 inhibitor approved for the treatment of metastatic or locally advanced epithelioid sarcoma in the United States. Additionally, Tazemetostat is being investigated in combination therapies for various cancers, including relapsed follicular lymphoma and high-risk diffuse large B-cell lymphoma, as well as in patients with platinum-resistant solid tumors and castration-resistant prostate cancer. Epizyme also works on other product candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, along with inhibitors targeting PRMT5 and PRMT1 for different types of cancers. Established in 2007, Epizyme collaborates with several prominent organizations to advance its research and development efforts.

BAKX Therapeutics is a company focused on developing innovative cancer treatments. It specializes in creating orally active therapeutics that target the mitochondrial apoptosis pathway, which plays a crucial role in cell death and cancer progression. By leveraging insights into the dynamic protein structures involved in this pathway, along with advanced structure-based drug design and computational simulations, BAKX aims to enhance the effectiveness and longevity of cancer therapies. The company's approach seeks to provide medical professionals with improved treatment options for cancer patients.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

Clementia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Montreal, Canada, focused on developing innovative treatments for patients with ultra-rare bone disorders and other diseases characterized by high unmet medical needs. Founded in 2010, the company specializes in disease-modifying therapies, with its lead product candidate being palovarotene, an oral small molecule. Palovarotene has demonstrated significant potential in preventing abnormal bone formation and fibrosis across various tissues. The candidate is currently undergoing evaluation in the Phase III MOVE trial, targeting conditions such as fibrodysplasia ossificans progressive and multiple osteochondromas, as well as dry eye disease. Clementia's commitment to addressing debilitating health issues highlights its role in advancing treatment options for affected patients.

Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 1993. The company focuses on discovering, designing, and developing innovative therapies for the treatment of cancer and autoimmune diseases. Merrimack employs a systems biology approach, utilizing multidisciplinary capabilities to create functional and predictive computational models of biological systems, particularly cell signaling networks. In addition to its internal development efforts, the company collaborates with third parties to further process and commercialize its products, enhancing its ability to bring novel therapeutics and diagnostics to market.

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for rare genetic disorders, particularly those that lead to life-threatening metabolic conditions. The company’s primary product candidate, setmelanotide, is a first-in-class melanocortin-4 receptor agonist currently undergoing Phase III clinical trials for the treatment of obesity related to pro-opiomelanocortin (POMC) and leptin receptor deficiencies, as well as Bardet-Biedl and Alström syndromes. Additionally, it is in Phase II trials for various other genetic obesity disorders. Rhythm Pharmaceuticals is also advancing RM-853, an orally available ghrelin o-acyltransferase inhibitor in preclinical development aimed at addressing Prader-Willi syndrome. Founded in 2008 and based in Boston, Massachusetts, the company previously operated under the name Rhythm Metabolic, Inc. and rebranded in October 2015.

Akkadeas Pharma srl, founded in 2007 and based in Milan, Italy, specializes in the production and sale of pharmaceutical products, food supplements, and medical devices aimed at alleviating symptoms and disturbances that affect patients' daily activities. The company's product line includes offerings such as OVERSAL, BBTONIK-500, PERGRILL, OVERSAL FOLIC, SKRIM 1G, and TROFIGARD. Additionally, Akkadeas Pharma distributes third-party products, enhancing its portfolio. The company primarily serves patients through family doctors and specialists, focusing on private healthcare expenditure. Their products originate from both proprietary development and collaborations with specialized companies, reflecting their commitment to improving individual well-being.

Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.

OctreoPharm Sciences GmbH is a biopharmaceutical company based in Berlin, Germany, specializing in the development of radiopharmaceuticals aimed at the diagnosis and treatment of neuroendocrine tumors. Founded in 2010, the company is engaged in creating theranostic antagonistic peptides that serve both diagnostic and therapeutic purposes. Its notable products include OPS201, designed for selective internal peptide receptor radionuclide therapy using radioisotopes like 90Y or 177Lu, and OPS202, which is a gallium-68 labeled somatostatin receptor antagonist intended for positron emission tomography. As of mid-2015, OctreoPharm Sciences operates as a subsidiary of Ipsen S.A.

Canbex Therapeutics, based in London, United Kingdom, focuses on developing peripherally-acting cannabinoid agonists aimed at treating spasticity associated with multiple sclerosis and other neurodegenerative disorders. Founded in 2005, the company is committed to addressing the debilitating symptoms of spasticity, which include involuntary muscle spasms and stiffness. Canbex's lead program seeks to enhance the quality of life for patients suffering from this challenging and incurable condition, with the aim of establishing a new standard in the management of spasticity.

Thesan Pharmaceuticals, Inc. is a biopharmaceutical company based in Carlsbad, California, established in 2011. It specializes in developing innovative therapeutics for skin disorders, particularly atopic dermatitis and acne. Unlike many companies that primarily reformulate existing treatments with limited advancements, Thesan is dedicated to discovering and developing New Chemical Entities aimed at significantly improving patient outcomes. Through its commitment to innovation, Thesan seeks to address the gaps in dermatological care and provide healthcare providers with effective treatment options for their patients.

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Motus Therapeutics is a biotechnology company based in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet medical needs in metabolic diseases, particularly gastrointestinal disorders. The company's lead product candidate, relamorelin, is a ghrelin agonist designed to treat diabetic gastroparesis, a complication associated with diabetes, as well as other gastrointestinal functional disorders. Motus Therapeutics aims to provide innovative solutions for patients suffering from these conditions.

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for rare genetic disorders, particularly those that lead to life-threatening metabolic conditions. The company’s primary product candidate, setmelanotide, is a first-in-class melanocortin-4 receptor agonist currently undergoing Phase III clinical trials for the treatment of obesity related to pro-opiomelanocortin (POMC) and leptin receptor deficiencies, as well as Bardet-Biedl and Alström syndromes. Additionally, it is in Phase II trials for various other genetic obesity disorders. Rhythm Pharmaceuticals is also advancing RM-853, an orally available ghrelin o-acyltransferase inhibitor in preclinical development aimed at addressing Prader-Willi syndrome. Founded in 2008 and based in Boston, Massachusetts, the company previously operated under the name Rhythm Metabolic, Inc. and rebranded in October 2015.

Motus Therapeutics is a biotechnology company based in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet medical needs in metabolic diseases, particularly gastrointestinal disorders. The company's lead product candidate, relamorelin, is a ghrelin agonist designed to treat diabetic gastroparesis, a complication associated with diabetes, as well as other gastrointestinal functional disorders. Motus Therapeutics aims to provide innovative solutions for patients suffering from these conditions.

Biomeasure, Inc., one of four research centers of the Ipsen Group to discover drugs in neuro-endocrinology, needed a multi-product, multi-purpose cGMP facility built on a fast track and a tight budget. Richmond started with a process to identify the goals of all Bio-measure stakeholders, continued with design & engineering coordination, achieved the budget through value engineering, and provided guaranteed costs & schedule. The results: 40,000 sf of cGMP manufacturing space, delivered in a short timeframe on a tight budget.

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Ipsen Pharmaceuticals, Inc. provides pharmaceutical products.

Octagen Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of treatments for hemophilia and genetic disorders related to the clotting process. Founded in 1997 and headquartered in Penn Valley, Pennsylvania, the company specializes in developing variations of recombinant B domain deleted porcine factor VIII, which are designed to evade immune system inactivation. As of July 2008, Octagen operates as a subsidiary of Ipsen S.A.

Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA. The company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A.

Sterix Ltd operates as a biopharmaceutical company that provides research and development services.

Genfit is a late-stage biopharmaceutical company specializing in the discovery and development of innovative therapeutic and diagnostic solutions for metabolic and liver-related diseases, addressing significant unmet medical needs. The company's research leverages its expertise in modulating gene expression through nuclear receptors, utilizing rational drug design to optimize drug candidates. With a strong foundation in scientific and clinical expertise, Genfit employs a translational, disease-driven approach and advanced bioinformatics capabilities to create a robust platform for drug discovery and development. Co-founded by Professor Bart Staels, a recognized expert in nuclear receptors, Genfit benefits from his leadership as chair of the Scientific Advisory Board, enhancing the company's commitment to innovation in the metabolic field. Through strategic alliances, acquisitions, and licensing agreements, Genfit seeks to fund the advancement of its products, which hinge on successful clinical development.